Skip to content
StockMarketAgent
Direct answer
IDXX trades against a final fair-value range of $231.99-$439.23, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $232, high $439, with mid-point at $335.
Stock analysis

IDXX IDXX fair value $232–$439

IDXX
By StockMarketAgent.AI team· supervised by
분석일: 2026-05-13다음 업데이트: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
주가
$533.92
▼ -198.84 (-37.24%)
공정 가치
$335
$232–$439
등급
매도
confidence 79/100
상승 여력
-37.2%
upside to fair value
안전 마진
$284.82
MoS level · 15%
시가총액
$42.1B
P/E fwd 32.4
영어 원본으로 대체KO
번역하는 동안 영어 원본을 표시 중
이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

§1 개요

  • Composite fair value $335 with high case $439.
  • Implied downside of 37.2% to fair value.
  • Moat 9/10 · confidence 79/100 · Mature compounder.
  • Currently screens above fair value, so patience matters more than entry speed.
Fair value
$335
Margin of safety
-59.3%
Confidence
79/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$533.92Price
Low $231.99
Mid $335.08
High $439.23

IDXX trades against a final fair-value range of $231.99-$439.23, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Razor-and-blade diagnostic instrument model
    Razor-and-blade diagnostic instrument model
  • High switching costs locking in
    High switching costs locking in veterinary clinics
  • Cycle upside
    Accelerating global pet humanization, increased diagnostic utilization per clinical visit, and ongoing margin expansion from software integration.

§2 베어 케이스

A prolonged macroeconomic downturn could reduce discretionary veterinary clinic traffic, stalling instrument placements and consumable volume growth, while a high starting valuation multiple compresses.

이 논제가 무너지는 경로

Severe Valuation Compression

· High

Market recalibrates the extreme 39x trailing P/E multiple down to the model's 25x terminal multiple constraint.

FV impact
-37% to base case midpoint of $335.08

Macroeconomic Traffic Downturn

· Medium

A prolonged recession reduces discretionary veterinary clinic traffic, stalling instrument placements and recurring consumable volumes.

FV impact
Drives valuation toward the $231.99 bear case low

Margin Degradation

· Low

Competition forces aggressive pricing, causing operating margins to fall below the historically stable 30-31.6% range.

FV impact
Erodes 41.7% ROIC and compresses intrinsic fair value further
모니터링할 조기 경보 신호
지표현재트리거 임계값
Operating margins falling below 30% indicating pricing power erosion.MonitorDeterioration versus the report thesis
Consumables volume growth dropping below mid-single digits.MonitorDeterioration versus the report thesis
Deceleration in new point-of-care instrument placements.MonitorDeterioration versus the report thesis
Market-implied growth expectations failing to meet the 15.29% hurdle.MonitorDeterioration versus the report thesis
Terminal multiple compression accelerating toward the 25x model anchor.MonitorDeterioration versus the report thesis

§3 재무 이력

손익계산서 — 최근 6기
항목T−0T−1T−2T−3T−4CAGR
기간2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
매출$3.22B$3.37B$3.66B$3.90B$4.30B+7.6%
매출총이익$1.89B$2.00B$2.19B$2.38B$2.66B+8.9%
영업이익$932.0M$898.8M$1.10B$1.13B$1.36B+9.9%
순이익$744.8M$679.1M$845.0M$887.9M$1.06B+9.2%
EPS (희석)$8.03$10.06$10.67$13.08+13.0%
EBITDA$1.04B$1.01B$1.22B$1.27B$1.51B+9.8%
R&D$161.0M$254.8M$191.0M$219.8M$251.2M+11.8%
판관비$796.4M$850.8M$901.9M$1.03B$1.05B+7.1%

품질 점수

OCF / 순이익
1.12×
>1은 이익의 질이 높음을 의미
회계 품질 게이트
Fail
섹터 조정 게이트
ROIC
41.7%
투하자본수익률
섹션 3

Numbers analysis

현금 흐름

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

자본 배분

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

개인 구독자 — §4부터11개 섹션 더

전체 분석 읽기 — 11개 섹션 더.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

모든 커버 종목에 대한 전체 보고서
24개월 등급 아카이브
관심 목록 브리핑 + 등급 변경 알림
모든 언어로 PDF + DOCX 내보내기
무료 체험 시작
언제든지 취소 가능.
FAQ

IDXX — frequently asked questions

  1. Based on our latest analysis, IDXX looks meaningfully overvalued. The current price is $534 versus a composite fair-value midpoint of $335 (range $232–$439), which implies roughly 37.2% downside to the midpoint.
Related coverage

Names readers of IDXX also follow

Same archetype: mature-compounder